

2004

SEQUENCE LISTING

AURELIUM BIOPHARMA INC.

<120> VIMENTIN DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR
MULTIDRUG RESISTANT NEOPLASTIC DISEASE

<130> 112418.147US

<140> 10/736,889

<141> 2003-12-15

<150> 60/433,480

<151> 2002-12-13

<160> 5

<170> PatentIn Ver. 3.2

<210> 1

<211> 466

<212> PRT

<213> Homo sapiens

<400> 1

Met	Ser	Thr	Arg	Ser	Val	Ser	Ser	Ser	Ser	Tyr	Arg	Arg	Met	Phe	Gly
1				5					10					15	

Gly	Pro	Gly	Thr	Ala	Ser	Arg	Pro	Ser	Ser	Ser	Arg	Ser	Tyr	Val	Thr
			20					25					30		

Thr	Ser	Thr	Arg	Thr	Tyr	Ser	Leu	Gly	Ser	Ala	Leu	Arg	Pro	Ser	Thr
		35					40					45			

Ser	Arg	Ser	Leu	Tyr	Ala	Ser	Ser	Pro	Gly	Gly	Val	Tyr	Ala	Thr	Arg
	50					55					60				

Ser	Ser	Ala	Val	Arg	Leu	Arg	Ser	Ser	Val	Pro	Gly	Val	Arg	Leu	Leu
65					70					75				80	

Gln	Asp	Ser	Val	Asp	Phe	Ser	Leu	Ala	Asp	Ala	Ile	Asn	Thr	Glu	Phe
			85						90					95	

Lys	Asn	Thr	Arg	Thr	Asn	Glu	Lys	Val	Glu	Leu	Gln	Glu	Leu	Asn	Asp
		100					105						110		

Arg	Phe	Ala	Asn	Tyr	Ile	Asp	Lys	Val	Arg	Phe	Leu	Glu	Gln	Gln	Asn
	115						120					125			

Lys	Ile	Leu	Leu	Ala	Glu	Leu	Glu	Gln	Leu	Lys	Gly	Gln	Gly	Lys	Ser
130						135					140				

Arg	Leu	Gly	Asp	Leu	Tyr	Glu	Glu	Glu	Met	Arg	Glu	Leu	Arg	Arg	Gln
145					150					155					160

Val	Asp	Gln	Leu	Thr	Asn	Asp	Lys	Ala	Arg	Val	Glu	Val	Glu	Arg	Asp
				165					170					175	



Asn Leu Ala Glu Asp Ile Met Arg Leu Arg Glu Lys Leu Gln Glu Glu
180 185 190

Met Leu Gln Arg Glu Glu Ala Glu Asn Thr Leu Gln Ser Phe Arg Gln
195 200 205

Asp Val Asp Asn Ala Ser Leu Ala Arg Leu Asp Leu Glu Arg Lys Val
210 215 220

Glu Ser Leu Gln Glu Glu Ile Ala Phe Leu Lys Lys Leu His Glu Glu
225 230 235 240

Glu Ile Gln Glu Leu Gln Ala Gln Ile Gln Glu Gln His Val Gln Ile
245 250 255

Asp Val Asp Val Ser Lys Pro Asp Leu Thr Ala Ala Leu Arg Asp Val
260 265 270

Arg Gln Gln Tyr Glu Ser Val Ala Ala Lys Asn Leu Gln Glu Ala Glu
275 280 285

Glu Trp Tyr Lys Ser Lys Phe Ala Asp Leu Ser Glu Ala Ala Asn Arg
290 295 300

Asn Asn Asp Ala Leu Arg Gln Ala Lys Gln Glu Ser Thr Glu Tyr Arg
305 310 315 320

Arg Gln Val Gln Ser Leu Thr Cys Glu Val Asp Ala Leu Lys Gly Thr
325 330 335

Asn Glu Ser Leu Glu Arg Gln Met Arg Glu Met Glu Glu Asn Phe Ala
340 345 350

Val Glu Ala Ala Asn Tyr Gln Asp Thr Ile Gly Arg Leu Gln Asp Glu
355 360 365

Ile Gln Asn Met Lys Glu Glu Met Ala Arg His Leu Arg Glu Tyr Gln
370 375 380

Asp Leu Leu Asn Val Lys Met Ala Leu Asp Ile Glu Ile Ala Thr Tyr
385 390 395 400

Arg Lys Leu Leu Glu Gly Glu Glu Ser Arg Ile Ser Leu Pro Leu Pro
405 410 415

Asn Phe Ser Ser Leu Asn Leu Arg Glu Thr Asn Leu Asp Ser Leu Pro
420 425 430

Leu Val Asp Thr His Ser Lys Arg Thr Phe Leu Ile Lys Thr Val Glu
435 440 445

Thr Arg Asp Gly Gln Val Ile Asn Glu Thr Ser Gln His His Asp Asp
450 455 460

Leu Glu
465

<210> 2
<211> 1766
<212> DNA
<213> Homo sapiens

<400> 2
cgcgccaccg ccgcccgcga ggccatcgcc accctccgca gccatgtcca ccagggtccgt 60
gtcctcgctc tcctaccgca ggatgttcgg cgccccgggc accgcgagcc ggccgagctc 120
cagccggagc tacgtgacta cgtccacccg cacctacagc ctgggcagcg cgtgcgccc 180
cagcaccagc cgcagcctct acgcctcgtc cccgggcggc gtgtatgcca cgcgctcctc 240
tgccgtgcgc ctgcccggagc gcgtgcccgg ggtgcggctc ctgcaggact cgggtggactt 300
ctcgcgtggcc gacgccatca acaccgagtt caagaacacc cgcaccaacg agaagggtgga 360
gctgcaggag ctgaatgacc gcttcgcca ctacatcgac aagggtgcgt tcctggagca 420
gcagaataag atcctgctgg ccgagctcga gcagctcaag ggccaaggca agtcgcgcct 480
ggggggacctc tacgaggagg agatgcggga gctgcgcccg cagggtggacc agctaaccac 540
cgacaaagcc cgcgtcgagg tggagcgcca caacctggcc gaggacatca tgcgcctccg 600
ggagaaattg caggaggaga tgcttcagag agaggaagcc gaaaacaccc tgcaatcttt 660
cagacaggat gttgacaatg cgtctctggc acgtcttgac cttgaacgca aagtggaatc 720
tttgcaagaa gagattgcct ttttgaagaa actccacgaa gaggaaatcc aggagctgca 780
ggctcagatt caggaacagc atgtccaaat cgatgtggat gtttccaagc ctgacctcac 840
ggctgccctg cgtgacgtac gtcagcaata tgaaagtgtg gctgccaaga acctgcagga 900
ggcagaagaa tgggtacaaat ccaagtttgc tgacctctct gaggctgcca accggaacaa 960
tgacgccctg cgccaggcaa agcaggagtc cactgagtag cggagacagg tgcagtccct 1020
cacctgtgaa gtggatgccc ttaaagggaac caatgagtag ctggaacgcc agatgcgtga 1080
aatggaagag aactttgccc ttgaagctgc taactaccaa gacactattg gccgcctgca 1140
ggatgagatt cagaatatga aggaggaaat ggctcgtcac cttcgtgaat accaagacct 1200
gctcaatgtt aagatggccc ttgacattga gattgccacc tacaggaagc tgctggaagg 1260
cgaggagagc aggatctctc tgccctcttc aaacttttcc tcctgaacc tgagggaaac 1320
taatctggat tcaactccctc tggttgatac ccaactcaaaa aggacacttc tgattaagac 1380
ggttgaaact agagatggac aggttatcaa cgaaacttct cagcatcacg atgacctga 1440
ataaaaattg cacacactca gtgcagcaat atattaccag caagaataaa aaagaaatcc 1500
atatcttaaa gaaacagctt tcaagtgcct ttctgcagtt tttcaggagc gcaagataga 1560
tttggaatag gaataagctc tagttcttaa caaccgacac tcctacaaga tttagaaaaa 1620
agttttacaac ataatttagt ttacagaaaa atcttgtgct agaatacttt ttaaaaggta 1680
ttttgaatac cattaaaact gctttttttt ttccagcaag tatccaacca acttggttct 1740
gcttcaataa atctttggaa aaacta 1766

<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
linker peptide

<220>
<221> MOD_RES
<222> (4)
<223> Leu-Dau

<400> 3
Ala Leu Ala Leu
1

<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
linker peptide

<220>
<221> MOD_RES
<222> (4)
<223> Gly-Dau

<400> 4
Gly Phe Leu Gly
1

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
linker peptide

<400> 5
Leu Ala Leu Ala
1